New hope for patients where CAR-T falls short
Disease control
Recruiting now
This early-stage study is testing a new two-drug combination for patients with B-cell lymphoma. It is for people whose cancer did not respond well enough to a powerful treatment called CAR-T therapy. The goal is to see if adding an oral drug (CC-99282) to an existing antibody dru…
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC